The drug company behind the oxycodone/naloxone combination drug Targin has been fined $300,000 by the TGA for misleading advertisements directed at GPs.

The ads, distributed in 2017 and 2018 by Mundipharma, included a statement that opioids “should be used as part of multimodal pain management plan and in an ongoing trial” because of risks of potential harms, including unsanctioned use, addiction and overdose.